Cover Image
市場調查報告書

生物醫藥品製造業的市場分析

Global Biopharmaceutical Manufacturing Market Report 2016-2021

出版商 IMARC Services Pvt. Ltd. 商品編碼 367472
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物醫藥品製造業的市場分析 Global Biopharmaceutical Manufacturing Market Report 2016-2021
出版日期: 2016年07月21日 內容資訊: 英文 110 Pages
簡介

本報告提供全球生物醫藥品製造業的市場、產業趨勢相關分析,近幾年的產業的主要趨勢,及整體市場趨勢、趨勢,各地區市場詳細趨勢,各地區、各細胞培養方式、各類藥物的市場規模、生產能力的變化及預測,過去、現在、未來的生產能力的變化,市場競爭環境,主要企業簡介等調查評估。

第1章 市場定義和分析方法

第2章 摘要整理

第3章 全球生物醫藥品市場:主要趨勢

第4章 全球生物醫藥品市場:產業趨勢

  • 過去、目前銷售額趨勢
  • 各地區的市場區隔
  • 各表現系統的市場區隔
  • 各產品種類的市場區隔
  • 市場未來展望

第5章 各國的生物醫藥品市場分析

  • 美國
    • 過去、目前銷售額趨勢
    • 市場未來展望
  • 加拿大
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 巴西
  • 澳洲

第6章 全球生物醫藥品製造業

  • 過去、目前生產能力趨勢
  • 各地區的市場區隔
    • 北美
    • 歐洲
    • 亞洲
  • 各生物培養方式的市場區隔
    • 哺乳類細胞培養
    • 微生物細胞培養
  • 各類藥物的市場區隔
    • 單株抗體
    • 基因改造蛋白質
    • 干擾素
    • 粗粒狀細胞聚落刺激因子 (G-CSF)
    • 促血紅細胞生長素
    • 基因改造型胰島素注射液
    • 疫苗
    • 人體生長荷爾蒙 (HGH)
  • 市場未來展望

第7章 競爭環境

  • 各製造商類型的市場區隔
    • 產品廠商
    • 受託製造企業
  • 主要企業簡介
    • Roche
    • Amgen
    • Novo Nordisk
    • AbbVie
    • Sanofi S.A
    • Johnson & Johnson
    • Pfizer
    • Merck & Co.
    • Lilly
    • Biogen Idec

圖表一覽

目錄
Product Code: SRP00116EO

IMARC Group's latest report titled "Global Biopharmaceutical Manufacturing Market Report 2016-2021" provides a detailed analysis on the global biopharmaceutical manufacturing market. Biopharmaceuticals represent one of the most elegant and sophisticated achievements of modern science. Compared to small molecules which are synthesized chemically, biopharmaceuticals or biologics are manufactured from biological sources and have proved to be efficacious in the treatment of various chronic and other rare diseases for which there are no available treatments. The production of biopharmaceuticals reliably at an industrial scale, however, involves highly complex manufacturing capabilities. This involves genetically engineered living cells that must be frozen for storage, thawed without causing any damage, and made to grow in the unusual environment of a reaction vessel. The molecules once produced must then be segregated from the living cells that produced them and the media in which they were made, all without damaging their complex, fragile structures. Such production facilities are also notably more expensive and involve longer time lines to build compared to small molecule drugs. These facilities are also significantly costlier to run, involving long process durations, low yields, costly raw materials, and require a team of highly skilled experts to operate them.

The efficacy and safety of biopharmaceuticals, coupled with their ability to address previously untreatable conditions, allows healthcare companies to command higher prices and margins for these drugs. Driven by their numerous advantages over conventional drugs, biopharmaceuticals today represent a big opportunity and represent more than 20% of the total global pharmaceutical sales. The current annual growth rate of biopharmaceuticals is also double that of conventional drugs, and growth is expected to remain robust for the foreseeable future. As a result of their rapid growth, many new players are entering this market and most current manufacturers are expanding their manufacturing capacities. Moreover, with the anticipated launch of a number of biosimilar drugs in the next five years, we expect a significant expansion in the global biopharmaceutical manufacturing capacity. We expect these trends to make biopharmaceutical manufacturing a very lucrative opportunity for investors and manufacturers.

Category Overview

The global biopharmaceutical manufacturing has been categorized on the basis of cell culture which includes mammalian cell culture and microbial cell culture. Currently, the largest number of biopharmaceutical products are manufactured using mammalian cell culture. Moreover, the mammalian-cell based products are more compatible with patients as these have been shown to cause minimum adverse reactions. As a result, there has been an increase in the mammalian based products over the past several years. Currently, mammalian cell culture holds a dominating share accounting for 56% in the total biopharmaceutical cell culture market. On the other hand, a significant growth has been observed in the microbial based products as well. A strong growth in the sales of dominant drugs such as Humalog, Lantus, Neupogen, Neulasta, and Betaseron/Betaferon have sustained the growth of biopharmaceutical manufacturing market.

On the basis of class, the market has been segmented as follows: Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Human Growth Hormones, Recombinant Human Insulin, Purified Proteins and Vaccines. Currently, Monoclonal Antibodies represents the fastest growing segment in this market.

Regional Market Overview

Currently, North America accounts for the largest biomanufacturing capacity followed by Europe and Asia. Technological advancements and high healthcare spending are some of the major factors that are driving the growth of the North American market. On the other hand, driven by factors such as emerging markets, increasing trends of contract manufacturing and a large patient pool, Asia will represent the fastest growing market.

Competitive landscape

In the recent past, the in-house manufacturing has experienced a shift towards contract manufacturing due to large volume requirements, cost saving measures and lack of expertise in particular segments of biopharmaceuticals. Currently, the contract manufacturing organisations (CMOs) accounts for around one third of the global biopharmaceutical capacities. The report also covers an in-depth analysis of the key companies operating in the global biopharmaceutical manufacturing market such as Pfizer Inc., Roche, Amgen Inc. Novo Nordisk, AbbVie Inc, Sanofi S.A, Eli Lilly, Johnson & Johnson, Merck Co., etc.

Table of Contents

1 Research Methodology and Market Definitions

2 Executive Summary

3 Global Biopharmaceutical Market: Key Trends

  • 3.1 Biopharmaceuticals are Growing Faster than Small Molecule Drugs
  • 3.2 Growth of Biosimilars will Push Volumes and Introduce New Players in this Market
  • 3.3 A Rich Biopharmaceutical Pipeline will Drive the Capacity Demand in the Coming Years
  • 3.4 Increasing Trends in Mergers and Acquisitions will Increase Redundant Capacities
  • 3.5 Increasing Focus on Personalized Medicines and High Value Low Volume Markets
  • 3.6 Higher Titers will Reduce Capacity Demand
  • 3.7 Growth in the Use of Cost Effective Disposable Technologies
  • 3.8 Despite Sufficient Global Capacity, Its Uneven Distribution will Continue to Spur Demand

4 Global Biopharmaceutical Market: Industry Performance

  • 4.1 Current and Historical Sales Trends
  • 4.2 Market Breakup by Region
  • 4.3 Market Breakup by Expression Systems
  • 4.4 Market Breakup by Product Type
  • 4.5 Market Outlook

5 Regional Biopharmaceutical Market Analysis

  • 5.1 United States
    • 5.1.1 Current and Historical Sales Trends
    • 5.1.2 Market Outlook
  • 5.2 Canada
    • 5.2.1 Current and Historical Sales Trends
    • 5.2.2 Market Outlook
  • 5.3 United Kingdom
    • 5.3.1 Current and Historical Sales Trends
    • 5.3.2 Market Outlook
  • 5.4 Germany
    • 5.4.1 Current and Historical Sales Trends
    • 5.4.2 Market Outlook
  • 5.5 France
    • 5.5.1 Current and Historical Sales Trends
    • 5.5.2 Market Outlook
  • 5.6 Italy
    • 5.6.1 Current and Historical Sales Trends
    • 5.6.2 Market Outlook
  • 5.7 Spain
    • 5.7.1 Current and Historical Sales Trends
    • 5.7.2 Market Outlook
  • 5.8 Russia
    • 5.8.1 Current and Historical Sales Trends
    • 5.8.2 Market Outlook
  • 5.9 Brazil
    • 5.9.1 Current and Historical Sales Trends
    • 5.9.2 Market Outlook
  • 5.10 Australia
    • 5.10.1 Current and Historical Sales Trends
    • 5.10.2 Market Outlook

6 Global Biopharmaceutical Manufacturing Industry

  • 6.1 Current and Historical Manufacturing Capacity Trends
  • 6.2 Market Breakup by Region
    • 6.2.1 North America
      • 6.2.1.1 Current and Historical Manufacturing Capacity Trends
      • 6.2.1.2 Market Outlook
    • 6.2.2 Europe
      • 6.2.2.1 Current and Historical Manufacturing Capacity Trends
      • 6.2.2.2 Market Outlook
    • 6.2.3 Asia
      • 6.2.3.1 Current and Historical Manufacturing Capacity Trends
      • 6.2.3.2 Market Outlook
  • 6.3 Market Breakup by Cell Culture
    • 6.3.1 Mammalian Cell Culture
      • 6.3.1.1 Key Market Drivers
      • 6.3.1.2 Current and Historical Sales Trends
      • 6.3.1.3 Current and Historical Manufacturing Capacity Trends
      • 6.3.1.4 Market Breakup by Region
      • 6.3.1.5 Market Breakup by Product Type
      • 6.3.1.6 Key Players
      • 6.3.1.7 Market Outlook
    • 6.3.2 Microbial Cell Culture
      • 6.3.2.1 Key Market Drivers
      • 6.3.2.2 Current and Historical Sales Trends
      • 6.3.2.3 Current and Historical Manufacturing Capacity Trends
      • 6.3.2.4 Market Breakup by Product
      • 6.3.2.5 Market Breakup by Region
      • 6.3.2.6 Key Players
      • 6.3.2.7 Market Outlook
  • 6.4 Market Breakup by Class
    • 6.4.1 Monoclonal Antibodies
      • 6.4.1.1 Current and Historical Sales Trends
      • 6.4.1.2 Market Outlook
    • 6.4.2 Recombinant Proteins
      • 6.4.2.1 Current and Historical Sales Trends
      • 6.4.2.2 Market Outlook
    • 6.4.3 Interferon
      • 6.4.3.1 Current and Historical Sales Trends
      • 6.4.3.2 Market Outlook
    • 6.4.4 Granulocyte Colony-Stimulating Factor (G-CSF)
      • 6.4.4.1 Current and Historical Sales Trends
      • 6.4.4.2 Market Outlook
    • 6.4.5 Erythropoietin
      • 6.4.5.1 Current and Historical Sales Trends
      • 6.4.5.2 Market Outlook
    • 6.4.6 Recombinant Human Insulin
      • 6.4.6.1 Current and Historical Sales Trends
      • 6.4.6.2 Market Outlook
    • 6.4.7 Vaccines
      • 6.4.7.1 Current and Historical Sales Trends
      • 6.4.7.2 Market Outlook
    • 6.4.8 Human Growth Hormones (HGH)
      • 6.4.8.1 Current and Historical Sales Trends
      • 6.4.8.2 Market Outlook
  • 6.5 Market Outlook

7 Competitive Landscape

  • 7.1 Market Breakup by Manufacturer Type
    • 7.1.1 Product Companies
    • 7.1.2 Contract Manufacturers
  • 7.2 Key Player Profiles
    • 7.2.1 Roche
      • 7.2.1.1 Company Overview
      • 7.2.1.2 Key Financials
    • 7.2.2 Amgen
      • 7.2.2.1 Company Overview
      • 7.2.2.2 Key Financials
    • 7.2.3 Novo Nordisk
      • 7.2.3.1 Company Overview
      • 7.2.3.2 Key Financials
    • 7.2.4 AbbVie
      • 7.2.4.1 Company Overview
      • 7.2.4.2 Key Financials
    • 7.2.5 Sanofi S.A
      • 7.2.5.1 Company Overview
      • 7.2.5.2 Key Financials
    • 7.2.6 Johnson & Johnson
      • 7.2.6.1 Company Overview
      • 7.2.6.2 Key Financials
    • 7.2.7 Pfizer
      • 7.2.7.1 Company Overview
      • 7.2.7.2 Key Financials
    • 7.2.8 Merck & Co.
      • 7.2.8.1 Company Overview
      • 7.2.8.2 Key Financials
    • 7.2.9 Lilly
      • 7.2.9.1 Company Overview
      • 7.2.9.2 Key Financials
    • 7.2.10 Biogen Idec
      • 7.2.10.1 Company Overview
      • 7.2.10.2 Key Financials

List of Figures

  • Figure 2 1: Global: Companies Manufacturing or Developing Active Substances for Follow-on Biologics (in no's)
  • Figure 2 2: Global: Biopharmaceutical Products: Distribution by Production Technology (in no's)
  • Figure 2 3: Global: Biopharmaceuticals: Mergers and Acquisitions Transaction Value (in US$ Billion)
  • Figure 2 4: Global: Orphan Drug Market: Designated vs Approvals (in no's), 2005-2015
  • Figure 2 5: Global: Personalized Medicine Market (in US$ Billion), 2009 and 2015
  • Figure 2 6: Increase in Titers and Reduction in Capacity Utilization Rate (in %), 2009 and 2015
  • Figure 2 7: Disposable (Single Use) vs Stainless Steel Bioreactors
  • Figure 2 8: United States and Western Europe: Capacity Expansion
  • Figure 3 1: Global: Biopharmaceutical Market: Sales Trend (in US$ Billion), 2008 - 2015
  • Figure 3 6: Global: Biopharmaceutical Market: Breakup by Region (in %), 2015
  • Figure 3 2: Global: Biopharmaceutical Market: Breakup by Various Expression Systems (in %), 2015
  • Figure 3 3: Global: Biopharmaceutical Market: Expression Systems (Respondents' Trends), 2008 - 2015
  • Figure 3 5: Global: Biopharmaceutical Market: Breakup by Drug Sales (in %), 2015
  • Figure 3 29: Global: Biopharmaceutical: Sales Trend Forecast (in US$ Billion), 2016- 2021
  • Figure 3 7: United States: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008 - 2015
  • Figure 3 8: United States: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 3 9: Canada: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008 - 2015
  • Figure 3 10: Canada: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 3 11: United Kingdom: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008-2015
  • Figure 3 12: United Kingdom: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 3 13: Germany: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008 - 2015
  • Figure 3 14: Germany: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 3 15: France: Biopharmaceutical Market: Sales Trend (in Million US$), 2008 - 2015
  • Figure 3 17: France: Biopharmaceutical Market: Sales Trend Forecast (in Million US$), 2016 - 2021
  • Figure 3 19: Italy: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008 - 2015
  • Figure 3 20: Italy: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 3 21: Spain: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008 - 2015
  • Figure 3 22: Spain: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 3 23: Russia: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008 - 2015
  • Figure 3 24: Russia: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 3 25: Brazil: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008 - 2015
  • Figure 3 26: Brazil: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 3 27: Australia: Biopharmaceutical Market: Sales Trend (in US$ Million), 2008 - 2015
  • Figure 3 28: Australia: Biopharmaceutical Market: Sales Trend Forecast (in US$ Million), 2016 - 2021
  • Figure 4 1: Global: Biopharmaceutical Manufacturing: Capacity Trends (in Kilo Liters), 2008-2015
  • Figure 4 2: Global: Biopharmaceuticals Manufacturing: Capacity Breakup by Region (in %), 2015
  • Figure 4 3: North America: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2008-2015
  • Figure 4 4: North America: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2016-2021
  • Figure 4 5: Europe: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2008-2015
  • Figure 4 6: Europe: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2016-2021
  • Figure 4 7: Asia: Biopharmaceuticals Manufacturing: Capacity Trend (in Kilo Liters), 2008-2015
  • Figure 4 8: Asia: Biopharmaceuticals Manufacturing: Capacity Trend Forecast (in Kilo Liters), 2016-2021
  • Figure 4 10: Global: Mammalian Products: Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 11: Global: Mammalian Cell Culture: Capacity Trend (in Kilo Liters), 2008-2015
  • Figure 4 12: Global: Mammalian Cell Culture: Capacity Utilization Trend (in %), 2008-2015
  • Figure 4 14: Global: Mammalian Cell Culture: Capacity Trends by Region (in Kilo Liters), 2008-2015
  • Figure 4 13: Global: Mammalian Cell Culture: Demand Breakup of Commercial Antibody Products (in %), 2015
  • Figure 4 15: Global: Mammalian Cell Culture: Market Breakup by Key Players (in %), 2015
  • Figure 4 16: Global: Mammalian Products: Sales Trend Forecast (in US$ Billion), 2016 - 2021
  • Figure 4 17: Global: Mammalian Cell Culture: Capacity Trend Forecast (in Kilo Liters), 2016 - 2021
  • Figure 4 18: Global: Mammalian Cell Culture: Capacity Trends Forecast by Region (in Kilo Liters), 2016-2021
  • Figure 4 19: Global: Microbial Products: Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 20: Global: Microbial Cell Culture: Capacity Trend (in Kilo Liters), 2008-2015
  • Figure 4 21: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trend (in Kilo Liters), 2008-2015
  • Figure 4 22: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trend (in Kilo Liters), 2008-2015
  • Figure 4 23: Global: Microbial Cell Culture: Capacity Utilization Trend (in %), 2008-2015
  • Figure 4 24: Global: Microbial Cell Culture: Demand Breakup of Commercial Products (in %), 2015
  • Figure 4 25: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trends by Region (in Kilo Liters), 2008-2015
  • Figure 4 26: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trends by Region (in Kilo Liters), 2008-2015
  • Figure 4 27: Global: Microbial Cell Culture: Market Breakup by Key Players (in %), 2015
  • Figure 4 28: Global: Microbial Products: Sales Trend Forecast (in US$ Billion), 2016- 2021
  • Figure 4 29: Global: Microbial Products: Capacity Trend Forecast (in Kilo Liters), 2016- 2021
  • Figure 4 30: Global: Microbial Cell Culture: Capacity (Commercial Volume) Trends Forecast by Region (in Kilo Liters), 2016- 2021
  • Figure 4 31: Global: Microbial Cell Culture: Capacity (Clinical Volume) Trends Forecast by Region (in Kilo Liters), 2016- 2021
  • Figure 4 32: Global: Monoclonal Antibodies: Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 33: Global: Monoclonal Antibodies: Sales Trend (in US$ Billion), 2016-2021
  • Figure 4 34: Global: Recombinant Proteins: Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 35: Global: Recombinant Proteins: Sales Trend Forecast (in US$ Billion), 2016-2021
  • Figure 4 36: Global: Interferon: Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 37: Global: Interferon: Sales Trend Forecast (in US$ Billion), 2016-2021
  • Figure 4 38: Global: Granulocyte Colony-Stimulating Factor (G-CSF): Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 39: Global: Granulocyte Colony-Stimulating Factor (G-CSF): Sales Trend Forecast (in US$ Billion), 2016-2021
  • Figure 4 40: Global: Erythropoietin: Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 41: Global: Erythropoietin: Sales Trend Forecast (in US$ Billion), 2016-2021
  • Figure 4 42: Global: Recombinant Human Insulin: Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 43: Global: Recombinant Human Insulin: Sales Trend Forecast (in US$ Billion), 2016-2021
  • Figure 4 44: Global: Vaccines: Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 45: Global: Vaccines: Sales Trend Forecast (in US$ Billion), 2016-2021
  • Figure 4 46: Global: Human Growth Hormones (HGH): Sales Trend (in US$ Billion), 2008-2015
  • Figure 4 47: Global: Human Growth Hormones (HGH): Sales Trend Forecast (in US$ Billion), 2016-2021
  • Figure 4 9: Global: Biopharmaceutical Manufacturing: Capacity Trend Forecast (In Kilo Liters), 2016-2021
  • Figure 5 1: Global: Biopharmaceutical Manufacturing: Capacity Breakup by Manufacturer Type (in %), 2015
  • Figure 5 2: Global: Biopharmaceutical Manufacturing: Capacity Breakup Forecast by Manufacturer Type (in %), 2021
  • Figure 5 3: Global: Biopharmaceutical Product Companies: Capacity Trend (in Kilo Liters), 2008 - 2015
  • Figure 5 4: Global: Biopharmaceutical Product Companies: Capacity Trend Forecast (in Kilo Liters), 2016 - 2021
  • Figure 5 5: Global: Biopharmaceutical CMOs: Capacity Trend (in Kilo Liters), 2008- 2015
  • Figure 5 6: Global: Biopharmaceutical CMOs: Capacity Trend Forecast (in Kilo Liters), 2016- 2021
  • Figure 6 1: Roche: Sales Value Trend (in Billion US$), 2011-2015
  • Figure 6 2: Roche: Revenue Breakup by Region (in %), 2015
  • Figure 6 3: Amgen: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 4: Amgen: Revenue Breakup by Region (in %), 2015
  • Figure 6 5: Novo Nordisk: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 6: Novo Nordisk: Revenue Breakup by Region (in %), 2015
  • Figure 6 7: AbbVie: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 8: AbbVie: Revenue Breakup by Region (in %), 2015
  • Figure 6 9: Sanofi S.A: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 10: Sanofi S.A: Revenue Breakup by Region (in %), 2015
  • Figure 6 11: Johnson & Johnson: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 12: Johnson & Johnson: Revenue Breakup by Region (in %), 2015
  • Figure 6 13: Pfizer: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 14: Pfizer: Revenue Breakup by Region (in %), 2015
  • Figure 6 15: Merck & Co: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 16: Merck & Co: Revenue Breakup by Region (in %), 2015
  • Figure 6 17: Lilly: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 18: Lilly: Revenue Breakup by Region (in %), 2015
  • Figure 6 19: Biogen Idec: Sales Value Trend (in Billion USD), 2011-2015
  • Figure 6 20: Biogen Idec: Revenue Breakup by Region (in %), 2015

List of Tables

  • Table 2 1: Global: Small Molecule Sales vs. Biopharmaceutical Sales (in Billion US$), 2008-2015
  • Table 6 1: Roche: Financial Data (2011-2015)
  • Table 6 2: Amgen: Financial Data (2011-2015)
  • Table 6 3: Novo Nordisk: Financial Data (2011-2015)
  • Table 6 4: AbbVie: Financial Data (2011-2015)
  • Table 6 5: Sanofi S.A: Financial Data (2011-2015)
  • Table 6 6: Johnson & Johnson: Financial Data (2011-2015)
  • Table 6 7: Pfizer: Financial Data (2011-2015)
  • Table 6 8: Merck & Co: Financial Data (2011-2015)
  • Table 6 9: Lilly: Financial Data (2011-2015)
  • Table 6 10: Biogen Idec: Financial Data (2011-2015)
Back to Top